Rhytab 7.5 mg:

Rhytab 7.5 mg tablet facilitates the individuals with chronic heart failure to lessen the probability of institutionalization for deteriorating heart failure.

Heart failure in children 6 months and older, with symptoms caused by an enlarged heart, may also be treated with this medication.

Composition:

Each film-coated tablet contains Ivabredine Hydrochloride MS 7.5 Mg and 5 Mg.

Brand: Sami Pharmaceuticals

Clinical Particulars:

Therapeutic Indications:

Symptomatic Treatment of chronic stable angina pectoris:

indicated for the symptomatic treatment of chronic stable angina pectoris coronary artery disease in adults with normal sinus rhythm and heart rate  > 70 BPM. Then

Ivabradine is indicated :

Adults who are unable to tolerate or with a contraindication to the use of beta-blocker.

Or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.

Treatment of chronic heart failure: ivabradine is indicated in the chronic heart failure NYHA LL to IV class with systolic dysfunction, inpatient in sinus rhythm, and whose heart rate is   > 75 BPM, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

How to get it: Purchase this product online by logging onto https://fareedpharma.com or calling +923005080963.

Dosage:

As physician advises and to be sold on the prescription of RMP only.

Special Warning and precaution for uses:

Special Warning:

Lack of benefit on clinical outcomes in patients with symptomatic chronic stable angina pectoris:

indicated only for symptomatic treatments of chronic stable angina pectoris because ivabradine has no benefit on cardiovascular outcomes (e.g mi infarction or cardiovascular death)